On Friday, Shares of Staples, Inc. (NASDAQ:SPLS), lost -0.27% to $16.38.
Staples, issued a statement in response to the vote by Office Depot shareholders approving the acquisition by Staples.
“We’re happy that Office Depot shareholders have overwhelmingly approved this transaction,” said Ron Sargent, Chairman and Chief Executive Officer, Staples. “The combined company will allow us to provide more value to customers and more effectively compete in a rapidly evolving environment.”
Staples received clearance for the transaction from regulatory agencies in New Zealand and China. The company is working closely with regulatory agencies to seek outstanding antitrust clearances and anticipates the transaction to be accomplished by the end of the year.
Staples, Inc., together with its auxiliaries, operates office products superstores. It operates through three segments: North American Stores & Online, North American Commercial, and International Operations.
Shares of Celgene Corporation (NASDAQ:CELG), inclined 0.26% to $117.22, during its last trading session.
Celgene Corporation, declared that during its June meeting the Company’s Board of Directors authorized the repurchase of up to an additional $4.0 billion of the Company’s common stock.
This open-ended program is effective right away. Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by Celgene’s administration and in accordance with the requirements of the Securities and Exchange Commission. Celgene now has a total of about $5.2 billion remaining from previous authorizations plus the new authorization. Since 2009, Celgene has returned about $12.3 billion to shareholders through the repurchase program.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Finally, BB&T Corporation (NYSE:BBT), ended its last trade with -0.63% loss, and closed at $41.02.
BB&T Corporation, declared the launch of a nondiscretionary dealer compensation program, providing a competitive automobile financing program that eliminates pricing discretion in the consumer transaction.
The program changes will go into effect on July 1, 2015, and will no longer allow dealer markup on retail installment sales contracts. BB&T Dealer Finance will instead offer a flat-fee dealer compensation program.
BB&T Corporation operates as a financial holding company that provides various banking and trust services for retail and commercial clients. It operates in six segments: Community Banking, Residential Mortgage Banking, Dealer Financial Services, Specialized Lending, Insurance Services, and Financial Services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
